China Medical System Holdings Ltd. Receives NMPA Approval to Begin Clinical Trials of MG-K10 Monoclonal Antibody Injection for COPD
Reuters
Yesterday
<a href="https://laohu8.com/S/CHSYF">China Medical System Holdings Ltd</a>. Receives NMPA Approval to Begin Clinical Trials of MG-K10 Monoclonal Antibody Injection for COPD
**China Medical System Holdings Ltd. Receives NMPA Approval to Begin Clinical Trials for Innovative COPD Drug** China Medical System Holdings Ltd. announced it has received approval from China's National Medical Products Administration (NMPA) to begin clinical trials of its innovative drug, MG-K10, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). MG-K10 is a long-acting anti-IL-4Rα humanized monoclonal antibody that targets type 2 inflammatory diseases by blocking IL-4 and IL-13 signaling pathways. The company holds co-development rights (excluding atopic dermatitis) and exclusive commercialization rights for MG-K10 in Mainland China, Hong Kong, Macao, Taiwan, and Singapore, following a collaboration agreement with Mabgeek Biotech and its subsidiary. The approval marks a significant step forward in expanding China Medical System's respiratory product portfolio and providing new treatment options for COPD patients in the region. No grant or funding from external agencies or multiple organizations was announced in connection with this regulatory approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.